Breaking: UBS Maintains $38.0 PT On Pfizer (NYSE:PFE) Shares, Maintains Their Original “Buy” Rating

January 23, 2018 - By reb123z

 Breaking: UBS Maintains $38.0 PT On Pfizer (NYSE:PFE) Shares, Maintains Their Original

Investors sentiment increased to 0.96 in Q3 2017. Its up 0.02, from 0.94 in 2017Q2. It is positive, as 53 investors sold Pfizer Inc. shares while 700 reduced holdings. 106 funds opened positions while 620 raised stakes. 4.06 billion shares or 0.86% more from 4.02 billion shares in 2017Q2 were reported.

Swiss State Bank stated it has 23.63M shares or 0.96% of all its holdings. The Texas-based Fayez Sarofim And has invested 0.13% in Pfizer Inc. (NYSE:PFE). Canada Pension Plan Invest Board holds 10.82 million shares or 0.79% of its portfolio. Moors And Cabot Incorporated owns 197,319 shares. 815,935 were accumulated by Cambridge Inv Advsr. Perkins Capital Mngmt Inc has 51,934 shares. Diamond Hill Cap Mgmt stated it has 2.09% of its portfolio in Pfizer Inc. (NYSE:PFE). 309.18M were reported by State Street. 210,832 were reported by Lehman Res. Natixis owns 3.50M shares for 1.15% of their portfolio. Nelson Roberts Investment Advsr Limited Liability Company accumulated 3,690 shares. Sectoral Asset Mngmt has 4.4% invested in Pfizer Inc. (NYSE:PFE). Creative Planning reported 745,352 shares. The New Jersey-based Economic Planning Inc Adv has invested 0.29% in Pfizer Inc. (NYSE:PFE). Wealthtrust Fairport Limited Company invested in 64,333 shares or 0.24% of the stock.

Since August 4, 2017, it had 0 buys, and 10 selling transactions for $16.36 million activity. On Friday, August 4 READ IAN C sold $3.30 million worth of Pfizer Inc. (NYSE:PFE) or 96,950 shares. Shares for $3.21 million were sold by DAMELIO FRANK A. JOHNSON RADY A sold $296,560 worth of stock. OLSON LAURIE J had sold 8,064 shares worth $263,693. 38,230 shares were sold by SUSMAN SALLY, worth $1.34 million on Tuesday, September 12.

Pfizer (NYSE:PFE) Rating Reaffirmed

In an analyst note revealed on Wednesday, 1 November, The “Buy” rating of Pfizer (NYSE:PFE) shares was maintained at UBS, who now has a $38.0 target price on the stock. UBS’s target price would indicate a possible upside of 2.93 % from the previous stock close of the company.

Investors sentiment increased to 0.96 in Q3 2017. Its up 0.02, from 0.94 in 2017Q2. It is positive, as 53 investors sold Pfizer Inc. shares while 700 reduced holdings. 106 funds opened positions while 620 raised stakes. 4.06 billion shares or 0.86% more from 4.02 billion shares in 2017Q2 were reported.

Swiss State Bank stated it has 23.63M shares or 0.96% of all its holdings. The Texas-based Fayez Sarofim And has invested 0.13% in Pfizer Inc. (NYSE:PFE). Canada Pension Plan Invest Board holds 10.82 million shares or 0.79% of its portfolio. Moors And Cabot Incorporated owns 197,319 shares. 815,935 were accumulated by Cambridge Inv Advsr. Perkins Capital Mngmt Inc has 51,934 shares. Diamond Hill Cap Mgmt stated it has 2.09% of its portfolio in Pfizer Inc. (NYSE:PFE). 309.18M were reported by State Street. 210,832 were reported by Lehman Res. Natixis owns 3.50M shares for 1.15% of their portfolio. Nelson Roberts Investment Advsr Limited Liability Company accumulated 3,690 shares. Sectoral Asset Mngmt has 4.4% invested in Pfizer Inc. (NYSE:PFE). Creative Planning reported 745,352 shares. The New Jersey-based Economic Planning Inc Adv has invested 0.29% in Pfizer Inc. (NYSE:PFE). Wealthtrust Fairport Limited Company invested in 64,333 shares or 0.24% of the stock.

Since August 4, 2017, it had 0 buys, and 10 selling transactions for $16.36 million activity. On Friday, August 4 READ IAN C sold $3.30 million worth of Pfizer Inc. (NYSE:PFE) or 96,950 shares. Shares for $3.21 million were sold by DAMELIO FRANK A. JOHNSON RADY A sold $296,560 worth of stock. OLSON LAURIE J had sold 8,064 shares worth $263,693. 38,230 shares were sold by SUSMAN SALLY, worth $1.34 million on Tuesday, September 12.

Pfizer Inc. (NYSE:PFE) Ratings Coverage

Among 21 analysts covering Pfizer (NYSE:PFE), 9 have Buy rating, 1 Sell and 11 Hold. Therefore 43% are positive. Pfizer has $54.0 highest and $33.0 lowest target. $38.67’s average target is 4.75% above currents $36.915 stock price. Pfizer had 68 analyst reports since July 29, 2015 according to SRatingsIntel. BMO Capital Markets maintained the stock with “Outperform” rating in Thursday, October 19 report. The firm has “Buy” rating given on Tuesday, October 31 by Piper Jaffray. The stock of Pfizer Inc. (NYSE:PFE) has “Buy” rating given on Wednesday, July 29 by Argus Research. The rating was upgraded by SunTrust on Wednesday, November 25 to “Neutral”. BMO Capital Markets maintained it with “Hold” rating and $3300 target in Tuesday, August 1 report. BMO Capital Markets maintained the shares of PFE in report on Friday, December 15 with “Buy” rating. Berenberg initiated it with “Hold” rating and $38 target in Thursday, May 12 report. The firm earned “Buy” rating on Tuesday, September 13 by Jefferies. The rating was maintained by SunTrust with “Hold” on Monday, October 16. The rating was maintained by Jefferies with “Buy” on Thursday, July 14.

The stock decreased 0.04% or $0.015 during the last trading session, reaching $36.915. About 7.83M shares traded. Pfizer Inc. (NYSE:PFE) has declined 2.76% since January 23, 2017 and is downtrending. It has underperformed by 19.46% the S&P500.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on January, 30. They expect $0.56 EPS, up 19.15 % or $0.09 from last year’s $0.47 per share. PFE’s profit will be $3.34 billion for 16.48 P/E if the $0.56 EPS becomes a reality. After $0.67 actual EPS reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -16.42 % negative EPS growth.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. The company has market cap of $220.04 billion. It operates through two divisions, Pfizer Innovative Health and Pfizer Essential Health (EH). It has a 22.8 P/E ratio. The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Investorplace.com which released: “Why Pfizer Inc. Stock Is One of the Few Safe Drug Stocks” on December 26, 2017, also Seekingalpha.com with their article: “Pfizer: The Best Big Pharma Dividend Stock” published on January 21, 2018, Fool.com published: “The case for Gilead Sciences” on January 21, 2018. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Seekingalpha.com and their article: “Hold On To Pfizer In 2018” published on December 29, 2017 as well as Investorplace.com‘s news article titled: “3 Reasons Dividend-Monster Pfizer Inc. Could Explode Higher” with publication date: January 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.